Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02410577 · ClinicalTrials.gov registry record · NA
89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT02410577: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02410577 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02410577, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to test a new imaging agent called 89Zr-J591 (stands for humanized antibody called J591, that is attached to a radioactive material called Zirconium-89) in patients with glioblastoma multiforme.
Interventions
- OTHER Blood draw
- DEVICE PET/CT Scan
- DEVICE MRI
- DRUG 89Zr-J591
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-04 |
| Est. Completion | 2018-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02410577
The ClinicalTrials.gov registry entry for NCT02410577 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Blood draw is the first listed.
NCT02410577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02410577 about?
NCT02410577 is a clinical study titled "89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme". The purpose of this study is to test a new imaging agent called 89Zr-J591 (stands for humanized antibody called J591, that is attached to a radioactive material called Zirconium-89) in patients with glioblastoma multiforme.
What is the current status of trial NCT02410577?
This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2015-04. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02410577?
The interventions under investigation include: Blood draw (OTHER), PET/CT Scan (DEVICE), MRI (DEVICE), 89Zr-J591 (DRUG).
Who is sponsoring clinical trial NCT02410577?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.